Credit: Eleonora Ghisoni / mIF stainings ILL platform / DO UNIL-CHUV
Credit: Eleonora Ghisoni / mIF stainings ILL platform / DO UNIL-CHUV This new research discovered that patients with metastatic melanoma who respond to adoptive T cell therapy exhibit a coordinated crosstalk between intratumoral myeloid cells and tumor-reactive CD8+ T cells. The study *, published in Science Immunology , was conducted by Dr David Barras, Dr Eleonora Ghisoni, Dr Johanna Chiffelle and colleagues and directed by Dr Denarda Dangaj and Pr George Coukos , members of the Lausanne Branch of the Ludwig Institute for Cancer Research. New findings from this research illuminate that individuals who respond positively to adoptive T cell therapy for metastatic melanoma demonstrate synchronized communication between myeloid cells within the tumor and tumor-reactive CD8+ T cells. In the ongoing quest to improve outcomes for metastatic melanoma, researchers have turned to adoptive cell therapy (ACT) using ex vivo-expanded tumor-infiltrating lymphocytes (TILs). While showing promise for some patients, its long-term effectiveness remains limited. Seeking new insights to enhance TIL-ACT responses, this research illuminate that individuals who respond positively to adoptive T cell therapy for metastatic melanoma demonstrate synchronized communication between myeloid cells within the tumor and tumor-reactive CD8+ T cells. The team examined longitudinal samples from 13 metastatic melanoma patients treated with TIL-ACT, after progression on immune checkpoint blockade therapies, in a phase 1 clinical study at the CHUV.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
